eft atrial appendage occlusion study III
Completed
- Conditions
- atrial fibrillationstroke10007521
- Registration Number
- NL-OMON44096
- Lead Sponsor
- Population Health Research Institute
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 150
Inclusion Criteria
Patients with atrial fibrillation undergoing cardiac surgery
Exclusion Criteria
Off-pump cardiac surgery
previous cardiac surgery
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>number of strokes</p><br>
- Secondary Outcome Measures
Name Time Method <p>1. Mortality<br /><br>2. post-operative safety outcomes: chest tube output in the first 24 hours<br /><br>post-surgery, post-operative re-exploration for bleeding within 48 hours, and<br /><br>30-day mortality<br /><br>3. incidence of re-hospitalization for heart failure<br /><br>4. incidence of major bleeding<br /><br>5. incidence of myocardial infarction</p><br>
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie eft atrial appendage occlusion in stroke prevention for atrial fibrillation patients in NL-OMON44096?
How does eft atrial appendage occlusion compare to anticoagulants like apixaban in reducing stroke risk for non-valvular atrial fibrillation in LAAOS III?
Which biomarkers predict optimal patient selection for eft left atrial appendage occlusion in the LAAOS III trial?
What adverse events are reported with eft atrial appendage occlusion in NL-OMON44096 and how are they managed in clinical practice?
How does eft left atrial appendage occlusion align with other percutaneous devices like Watchman in stroke risk mitigation for atrial fibrillation?